Lyrica® has been approved for treatment of postherpetic neuralgia
Tokyo, Japan, April 16, 2010 — Pfizer Japan Inc. (Head Office: Tokyo; President: Ichiro Umeda) announced that Lyrica® Capsules (generic name: pregabalin) has been approved today in Japan for the treatment of postherpetic neuralgia.
This product will be jointly promoted in Japan by Pfizer Japan Inc. and Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito).
Lyrica was developed by Pfizer Inc. (USA) and is currently approved in over 105 countries worldwide. Its major mode of action is thought to express its analgesic effects by suppressing the output of various neurotransmitters from overexcited nerves. The efficacy and safety of Lyrica have already been proven in a number of clinical trials. Lyrica is also listed as a first-line drug in the treatment guidelines/algorithm for neuropathic pain (including postherpetic neuralgia) in the United States and Europe.
Postherpetic neuralgia (PHN) is a disorder representative of peripheral neuropathic pain caused by nerve damage. Herpes zoster appears when viral resistance is lowered due to latent neuromuscular infection by varicella / herpes zoster viruses following first infection with chicken pox. PHN is considered an intractable pain, and symptoms include continued burning or electric shock-like pain after skin symptoms of herpes zoster have healed.
Lyrica has an entirely new mode of action from existing analgesic treatments, and domestic phase 3 trials have confirmed the efficacy and safety of its analgesic effects. It is also under review for indication approval for peripheral neuropathy, and development is underway to secure indication for fibromyalgia.
With this approval, Pfizer Japan Inc. and Eisai Co., Ltd. will contribute to the QOL improvement for patients with PHN by providing Lyrica Capsules as a new treatment.
Pfizer Japan Inc.
Public Relations Department
Eisai Co., Ltd.
Outline of Lyrica®